Study of time-course changes in annual recurrence rates for breast cancer: Data analysis of 2,209 patients for 10 years post-surgery

Breast Cancer Research and Treatment

Volumn 106, Issue 3, 2007, Pages 407-411

  Kimura, Morihiko ^a   Yanagita, Yasuhiro ^b   Fujisawa, Tomomi ^b   Koida, Tokihiro ^c  

^a General Ota Hospital   (Japan)

^b Gunma Cancer Centre   (Japan)

^c Kounan Hospital   (Japan)

Author keywords

Aromatase inhibitor; Breast cancer; Chemotherapy; Hormone receptor; Hormone therapy; Lymph node; Recurrence; Risk; Surgery; Venous invasion

Indexed keywords

HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER INVASION; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TIME FACTORS;

EID: 35648980474     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9510-2     Document Type: Article

References (9)

1. Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569-1583
2. Miura S (1989) Recurrence and follow-up after surgery. Jpn J Breast Cancer 4:181-190
3. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746
4. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930-942
5. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
6. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
7. Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462
8. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271
9. Jakesz R, Samonigg H, Greil R et al (2005) Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol (Meeting Abstracts) 23:10s